Company Overview of Galera Therapeutics, Inc.
Galera Therapeutics, Inc., a clinical-stage biotechnology company, develops drugs targeting oxygen metabolic pathways. The company primarily focuses on the prevention of radiation-induced toxicity, including mucositis, and the treatment of cancer. Its small molecule dismutase mimetics mimics the activity of the human superoxide dismutase enzymes. The company was founded in 2009 and is based in Malvern, Pennsylvania.
2 West Liberty Boulevard
Malvern, PA 19355
Founded in 2009
Key Executives for Galera Therapeutics, Inc.
Chief Executive Officer, President and Director
Founder, Chief Operating Officer and Director
Director of Business Development
Compensation as of Fiscal Year 2015.
Galera Therapeutics, Inc. Key Developments
Galera Therapeutics Announces Fast Track Designation of GC4419 for Prevention of Oral Mucositis
Jan 7 16
Galera Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for GC4419, an investigational drug candidate, for the reduction of severity and incidence of radiation and chemotherapy induced oral mucositis (OM). Galera also announced that it has begun enrolling patients in a Phase 2b study of GC4419 for the reduction of OM in head and neck cancer (HNC) patients. The FDA Fast Track process is designed to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. This designation provides for more frequent consultation between the FDA and the sponsor, as well as the potential "rolling review" of completed sections of the New Drug Application (NDA), and potential eligibility for accelerated approval and priority review. Based on Phase 1b/2a trial results of GC4419 in HNC patients receiving chemoradiation therapy, Galera has begun enrolling patients in a double-blind, randomized Phase 2b clinical trial to prevent OM in this setting.
Galera Therapeutics Appoints Thomas Dyrberg to the Board of Directors
Oct 14 15
Galera Therapeutics, Inc. announced it has completed a $37 million Series B financing. The Series B financing was led by Novo Ventures, with participation from existing investors New Enterprise Associates, Novartis Venture Fund (NVF), Correlation Ventures and Galera Angels. Dr. Thomas Dyrberg, Managing Partner of Novo Ventures, will join the Galera Board of Directors.
Galera Therapeutics, Inc. Presents at Boston CEO Conference, May-27-2015 01:00 PM
Apr 16 15
Galera Therapeutics, Inc. Presents at Boston CEO Conference, May-27-2015 01:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Robert A. Beardsley, Executive Chair of the Board of Directors.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 1, 2015